Skip to main content
Health InsuranceLGBTQ+Premium Insurance Assistance ProgramRyan White HIV/AIDS

Lenacapavir: A Twice-Yearly Injection Offering Hope in the Fight Against HIV

July 9, 2025

A New Era in HIV Prevention

In June 2025, the FDA approved lenacapavir (brand name Yeztugo) as the first twice-yearly injectable pre-exposure prophylaxis (PrEP) for HIV prevention. This long-acting treatment has shown remarkable efficacy—96% in cisgender women and 100% in men who have sex with men and gender-diverse individuals—offering a transformative alternative to daily PrEP pills.

Unlike daily oral medications, lenacapavir requires only two injections per year, potentially improving adherence and reducing new HIV infections, especially in populations where daily medication is challenging.

The Promise and the Challenges

While lenacapavir represents a significant advancement, its success depends on accessibility and affordability:

  • Cost Concerns: The annual price for Yeztugo is set at $28,218, which may be prohibitive for many.

  • Global Access: Gilead Sciences has partnered with the Global Fund to supply lenacapavir to low-income countries, aiming to reach up to 2 million people over three years.

  • Infrastructure Needs: Administering the injection requires healthcare infrastructure and regular HIV testing, which may be lacking in some regions.

Addressing these challenges is crucial to ensure that lenacapavir reaches those who could benefit most from its protective effects.

How American Exchange Can Help

At American Exchange, we understand the complexities of healthcare access and the importance of staying ahead with innovative solutions. Our platform can assist healthcare providers and organizations by:

  • Streamlining Enrollment: Facilitating patient enrollment in PrEP programs, including those involving lenacapavir.

  • Enhancing Outreach: Implementing targeted outreach strategies to educate communities about new HIV prevention options.

  • Ensuring Compliance: Providing tools to manage and monitor patient adherence to PrEP regimens.

👉 Schedule a demo to learn how American Exchange can support your organization’s efforts in HIV prevention and healthcare access.

Source:
PBS NewsHour. “How a new twice-yearly drug is prompting hopes of curbing HIV cases.” July 1, 2025. Available at: https://www.pbs.org/newshour/show/how-a-new-twice-yearly-drug-is-prompting-hopes-of-curbing-hiv-casespbs.org+1pbs.org+1